5500S-13: E5508 NSCLC

CTSU E5508: Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Type of Study
Cancer (Oncology) - Lung
Location
Swedish Cancer Institute
Short Description
Purpose: This randomized phase III trial is studying bevacizumab and pemetrexed disodium alone or in combination after induction therapy to see how well they work in treating patients with advanced non-squamous non-small cell lung cancer.
Status
Open to Enrollment
Principal Investigator
Gary Goodman, M.D.
Eligibility Notes
  • Cytologically or histologically confirmed non-small cell lung cancer (NSCLC)
    • Predominant non-squamous histology
      • NSCLC not otherwise specified allowed
      • Mixed tumors are categorized by the predominant cell type
  • Must meet 1 of the following criteria:
    • Stage IV disease including M1a or M1b stages or recurrent disease
    • Stage IIIB (T4NX) disease with ipsilateral lung lobe allowed provided patients are not candidates for combined chemotherapy or radiotherapy
  • Patient must have an overall stable or better response after 4 courses of induction therapy
  • ECOG performance status 0-1
  • At least 12 months since prior adjuvant chemotherapy
  • At least 2 weeks since prior radiotherapy
  • Patients must not have had any major surgery such as thoracotomy, laparotomy, craniotomy, or significant traumatic injury within 6 weeks prior to registration
  • No prior systemic chemotherapy for advanced stage lung cancer
  • No prior paclitaxel, pemetrexed disodium, or bevacizumab
    • Prior carboplatin allowed provided it was given as part of adjuvant chemotherapy
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
Phone
(206) 215-3086
Email
CancerResearch@swedish.org